Cellosaurus BT-20 (CVCL_0178)

Cell line name BT-20
Synonyms BT 20; BT20
Accession CVCL_0178
Resource Identification Initiative To cite this cell line use: BT-20 (RRID:CVCL_0178)
Comments Group: Triple negative breast cancer (TNBC) cell line.
Part of: Cancer Cell Line Encyclopedia (CCLE) project.
Part of: EGFR genetic alteration cell panel (ATCC TCP-1027).
Part of: ICBP43 breast cancer cell line panel.
Part of: KuDOS 95 cell line panel.
Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
Part of: PI3K genetic alteration cell panel (ATCC TCP-1028).
Doubling time: 70 hours (PubMed=25984343).
Microsatellite instability: Stable (MSS) (PubMed=12661003; Sanger).
Omics: CNV analysis.
Omics: Deep exome analysis.
Omics: Deep RNAseq analysis.
Omics: DNA methylation analysis.
Omics: miRNA expression profiling.
Omics: Protein expression by reverse-phase protein arrays.
Omics: shRNA library screening.
Omics: SNP array analysis.
Omics: Transcriptome analysis.
Disease Invasive ductal carcinoma, not otherwise specified (NCIt: C4194)
Species of origin Homo sapiens (Human) (NCBI Taxonomy: 9606)
Hierarchy Children: CVCL_J244 (BT-20/CMV-Luc); CVCL_M061 (BT-20/nKR)
Sex of cell Female
Category Cancer cell line
STR profile Source(s): AddexBio; ATCC; CLS; Cosmic-CLP; KCLB; PubMed=25877200

Markers:
AmelogeninX
CSF1PO12
D13S31711
D16S53911,14 (AddexBio; ATCC; CLS; Cosmic-CLP)
11 (PubMed=25877200)
D18S5117
D21S1128,29
D3S135817
D5S81812
D7S82010
D8S117912
FGA22,24
Penta D10,11
Penta E11,13
TH017,9.3
TPOX11
vWA16,17
Web pages http://www.pawefish.path.cam.ac.uk/BreastCellLineDescriptions/BT20.html
http://colt.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=BT-20
http://www.cells-talk.com/index.php/page/copelibrary?key=BT-20
http://lincs.hms.harvard.edu/resources/reagents/icbp43/
Publications

PubMed=13611537; DOI=10.1093/jnci/21.6.1131
Lasfargues E.Y., Ozzello L.
Cultivation of human breast carcinomas.
J. Natl. Cancer Inst. 21:1131-1147(1958)

PubMed=4831449; DOI=10.1093/jnci/52.5.1669
Ozzello L., Sordat B., Merenda C., Carrel S., Hurlimann J., Mach J.P.
Transplantation of a human mammary carcinoma cell line (BT 20) into nude mice.
J. Natl. Cancer Inst. 52:1669-1672(1974)

PubMed=833871; DOI=10.1093/jnci/58.2.209
Fogh J., Wright W.C., Loveless J.D.
Absence of HeLa cell contamination in 169 cell lines derived from human tumors.
J. Natl. Cancer Inst. 58:209-214(1977)

DOI=10.1007/978-1-4757-0019-0_7
Lasfargues E.Y., Coutinho W.G.
Human breast tumor cells in culture; new concepts in mammary carcinogenesis.
(In) New frontiers in mammary pathology; Hollmann K.H., de Brux J., Verley J.M. (eds.); pp.117-143; Plenum Press; New York (1981)

PubMed=7459858
Rousset M., Zweibaum A., Fogh J.
Presence of glycogen and growth-related variations in 58 cultured human tumor cell lines of various tissue origins.
Cancer Res. 41:1165-1170(1981)

PubMed=6220172
Dracopoli N.C., Fogh J.
Polymorphic enzyme analysis of cultured human tumor cell lines.
J. Natl. Cancer Inst. 70:469-476(1983)

PubMed=6582512; DOI=10.1073/pnas.81.2.568
Mattes M.J., Cordon-Cardo C., Lewis J.L. Jr., Old L.J., Lloyd K.O.
Cell surface antigens of human ovarian and endometrial carcinoma defined by mouse monoclonal antibodies.
Proc. Natl. Acad. Sci. U.S.A. 81:568-572(1984)

PubMed=3518877; DOI=10.3109/07357908609038260
Fogh J.
Human tumor lines for cancer research.
Cancer Invest. 4:157-184(1986)

PubMed=11414198; DOI=10.1007/s004320000207
Lahm H., Andre S., Hoeflich A., Fischer J.R., Sordat B., Kaltner H., Wolf E., Gabius H.J.
Comprehensive galectin fingerprinting in a panel of 61 human tumor cell lines by RT-PCR and its implications for diagnostic and therapeutic procedures.
J. Cancer Res. Clin. Oncol. 127:375-386(2001)

PubMed=11789735; DOI=10.1309/4NCM-QJ9W-QM0J-6QJE
Rhodes A., Jasani B., Couturier J., McKinley M.J., Morgan J.M., Dodson A.R., Navabi H., Miller K.D., Balaton A.J.
A formalin-fixed, paraffin-processed cell line standard for quality control of immunohistochemical assay of HER-2/neu expression in breast cancer.
Am. J. Clin. Pathol. 117:81-89(2002)

PubMed=12661003; DOI=10.1002/gcc.10196
Seitz S., Wassmuth P., Plaschke J., Schackert H.K., Karsten U., Santibanez-Koref M.-F., Schlag P.M., Scherneck S.
Identification of microsatellite instability and mismatch repair gene mutations in breast cancer cell lines.
Genes Chromosomes Cancer 37:29-35(2003)

PubMed=12800145; DOI=10.1002/gcc.10218
Adelaide J., Huang H.-E., Murati A., Alsop A.E., Orsetti B., Mozziconacci M.-J., Popovici C., Ginestier C., Letessier A., Basset C., Courtay-Cahen C., Jacquemier J., Theillet C., Birnbaum D., Edwards P.A.W., Chaffanet M.
A recurrent chromosome translocation breakpoint in breast and pancreatic cancer cell lines targets the neuregulin/NRG1 gene.
Genes Chromosomes Cancer 37:333-345(2003)

PubMed=16397213; DOI=10.1158/0008-5472.CAN-05-2853
Elstrodt F., Hollestelle A., Nagel J.H.A., Gorin M., Wasielewski M., van den Ouweland A., Merajver S.D., Ethier S.P., Schutte M.
BRCA1 mutation analysis of 41 human breast cancer cell lines reveals three new deleterious mutants.
Cancer Res. 66:41-45(2006)

PubMed=17157791; DOI=10.1016/j.ccr.2006.10.008
Neve R.M., Chin K., Fridlyand J., Yeh J., Baehner F.L., Fevr T., Clark L., Bayani N., Coppe J.P., Tong F., Speed T., Spellman P.T., DeVries S., Lapuk A., Wang N.J., Kuo W.L., Stilwell J.L., Pinkel D., Albertson D.G., Waldman F.M., McCormick F., Dickson R.B., Johnson M.D., Lippman M., Ethier S.P., Gazdar A.F., Gray J.W.
A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes.
Cancer Cell 10:515-527(2006)

PubMed=19582160; DOI=10.1371/journal.pone.0006146
Kao J., Salari K., Bocanegra M., Choi Y.-L., Girard L., Gandhi J., Kwei K.A., Hernandez-Boussard T., Wang P., Gazdar A.F., Minna J.D., Pollack J.R.
Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery.
PLoS ONE 4:E6146-E6146(2009)

PubMed=21778573; DOI=10.3233/BD-2010-0307
Chavez K.J., Garimella S.V., Lipkowitz S.
Triple negative breast cancer cell lines: one tool in the search for better treatment of triple negative breast cancer.
Breast Dis. 32:35-48(2010)

PubMed=22460905; DOI=10.1038/nature11003
Barretina J.G., Caponigro G., Stransky N., Venkatesan K., Margolin A.A., Kim S., Wilson C.J., Lehar J., Kryukov G.V., Sonkin D., Reddy A., Liu M., Murray L., Berger M.F., Monahan J.E., Morais P., Meltzer J., Korejwa A., Jane-Valbuena J., Mapa F.A., Thibault J., Bric-Furlong E., Raman P., Shipway A., Engels I.H., Cheng J., Yu G.K., Yu J., Aspesi P. Jr., de Silva M., Jagtap K., Jones M.D., Wang L., Hatton C., Palescandolo E., Gupta S., Mahan S., Sougnez C., Onofrio R.C., Liefeld T., MacConaill L., Winckler W., Reich M., Li N., Mesirov J.P., Gabriel S.B., Getz G., Ardlie K., Chan V., Myer V.E., Weber B.L., Porter J., Warmuth M., Finan P., Harris J.L., Meyerson M., Golub T.R., Morrissey M.P., Sellers W.R., Schlegel R., Garraway L.A.
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity.
Nature 483:603-607(2012)

PubMed=23151021; DOI=10.1186/1471-2164-13-619
Grigoriadis A., Mackay A., Noel E., Wu P.J., Natrajan R., Frankum J., Reis-Filho J.S., Tutt A.
Molecular characterisation of cell line models for triple-negative breast cancers.
BMC Genomics 13:619-619(2012)

PubMed=23601657; DOI=10.1186/bcr3415
Riaz M., van Jaarsveld M.T.M., Hollestelle A., Prager-van der Smissen W.J.C., Heine A.A.J., Boersma A.W.M., Liu J., Helmijr J.C.A., Ozturk B., Smid M., Wiemer E.A., Foekens J.A., Martens J.W.M.
miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs.
Breast Cancer Res. 15:R33-R33(2013)

PubMed=24176112; DOI=10.1186/gb-2013-14-10-r110
Daemen A., Griffith O.L., Heiser L.M., Wang N.J., Enache O.M., Sanborn Z., Pepin F., Durinck S., Korkola J.E., Griffith M., Hur J.S., Huh N., Chung J., Cope L., Fackler M.J., Umbricht C., Sukumar S., Seth P., Sukhatme V.P., Jakkula L.R., Lu Y., Mills G.B., Cho R.J., Collisson E.A., van't Veer L.J., Spellman P.T., Gray J.W.
Modeling precision treatment of breast cancer.
Genome Biol. 14:R110.1-R110.14(2013)

PubMed=25984343; DOI=10.1038/sdata.2014.35
Cowley G.S., Weir B.A., Vazquez F., Tamayo P., Scott J.A., Rusin S., East-Seletsky A., Ali L.D., Gerath W.F.J., Pantel S.E., Lizotte P.H., Jiang G., Hsiao J., Tsherniak A., Dwinell E., Aoyama S., Okamoto M., Harrington W., Gelfand E., Green T.M., Tomko M.J., Gopal S., Wong T.C., Li H., Howell S., Stransky N., Liefeld T., Jang D., Bistline J., Hill Meyers B., Armstrong S.A., Anderson K.C., Stegmaier K., Reich M., Pellman D., Boehm J.S., Mesirov J.P., Golub T.R., Root D.E., Hahn W.C.
Parallel genome-scale loss of function screens in 216 cancer cell lines for the identification of context-specific genetic dependencies.
Sci. Data 1:140035-140035(2014)

PubMed=25485619; DOI=10.1038/nbt.3080
Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z., Liu H., Degenhardt J., Mayba O., Gnad F., Liu J., Pau G., Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M., Zynda G.J., Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L., Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J., Settleman J., Seshagiri S., Zhang Z.
A comprehensive transcriptional portrait of human cancer cell lines.
Nat. Biotechnol. 33:306-312(2015)

PubMed=27397505; DOI=10.1016/j.cell.2016.06.017
Iorio F., Knijnenburg T.A., Vis D.J., Bignell G.R., Menden M.P., Schubert M., Aben N., Goncalves E., Barthorpe S., Lightfoot H., Cokelaer T., Greninger P., van Dyk E., Chang H., de Silva H., Heyn H., Deng X., Egan R.K., Liu Q., Mironenko T., Mitropoulos X., Richardson L., Wang J., Zhang T., Moran S., Sayols S., Soleimani M., Tamborero D., Lopez-Bigas N., Ross-Macdonald P., Esteller M., Gray N.S., Haber D.A., Stratton M.R., Benes C.H., Wessels L.F.A., Saez-Rodriguez J., McDermott U., Garnett M.J.
A landscape of pharmacogenomic interactions in cancer.
Cell 166:740-754(2016)

Cross-references
Cell line collections AddexBio; C0006014/4910
ATCC; CRL-7912 - Discontinued
ATCC; HTB-19
CLS; 300130/p656_BT-20
KCLB; 60061
NCBI_Iran; C434
Cell line databases/resources CLDB; cl493
CLDB; cl494
CLDB; cl495
CCLE; BT20_BREAST
CCRID; 3111C0001CCC000335
Cosmic-CLP; 906801
GDSC; 906801
IGRhCellID; BT20
LINCS_HMS; 50105
LINCS_LDP; LCL-1476
Lonza; 114
TOKU-E; 693
Ontologies BTO; BTO:0001466
CLO; CLO_0002041
EFO; EFO_0001092
MCCL; MCC:0000069
Biological sample resources BioSample; SAMN03471671
BioSample; SAMN03472738
Chemistry resources ChEMBL-Cells; CHEMBL3307766
ChEMBL-Targets; CHEMBL613870
Gene expression databases GEO; GSM184390
GEO; GSM184391
GEO; GSM350505
GEO; GSM459725
GEO; GSM783945
GEO; GSM827574
GEO; GSM847197
GEO; GSM847452
GEO; GSM843445
GEO; GSM843446
GEO; GSM886891
GEO; GSM887956
GEO; GSM1053689
GEO; GSM1172940
GEO; GSM1374406
GEO; GSM1374407
GEO; GSM1401673
GEO; GSM1669629
Polymorphism and mutation databases Cosmic; 687463
Cosmic; 871137
Cosmic; 904350
Cosmic; 906801
Cosmic; 934519
Cosmic; 979719
Cosmic; 991332
Cosmic; 997914
Cosmic; 1010923
Cosmic; 1017159
Cosmic; 1018465
Cosmic; 1046932
Cosmic; 1047701
Cosmic; 1136370
Cosmic; 1287931
Cosmic; 1289382
Cosmic; 1434946
Cosmic; 1524352
Cosmic; 1603190
Cosmic; 1609471
Cosmic; 1995348
Cosmic; 2009507
Cosmic; 2036672
Cosmic; 2301232
Cosmic; 2301522
Cosmic; 2307195
Cosmic; 2318378
Cosmic; 2361352